- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
- Interventions
- Sparsentan
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 10:54 PM EDT